1. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534.
[CROSSREF] [PUBMED] [PDF]
2. Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009;23:575-596.
[CROSSREF] [PUBMED]
3. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998;352:1455-1461.
[CROSSREF] [PUBMED]
4. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-4775.
[CROSSREF] [PUBMED] [PDF]
5. Oh MC, Kunwar S, Blevins L, Aghi MK. Medical versus surgical management of prolactinomas. Neurosurg Clin N Am 2012;23:669-678.
[CROSSREF] [PUBMED]
6. Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol 2011;7:267-278.
[CROSSREF] [PUBMED] [PDF]
7. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256-5261.
[CROSSREF] [PUBMED]
8. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-273.
[CROSSREF] [PUBMED]
9. Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454-456.
[CROSSREF] [PUBMED]
10. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-883.
[CROSSREF] [PUBMED] [PDF]
11. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005;8:43-52.
[CROSSREF] [PUBMED] [PDF]
12. Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 2012;166:779-786.
[CROSSREF]
13. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008;93:4721-4727.
[CROSSREF] [PUBMED] [PDF]
14. Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 2010;95:2672-2679.
[CROSSREF] [PUBMED]
15. Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 2012;167:651-662.
[CROSSREF] [PUBMED]
16. Yang MS, Hong JW, Lee SK, Lee EJ, Kim SH. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. J Neurooncol 2011;104:195-204.
[CROSSREF] [PUBMED] [PDF]
17. Di Chiro G, Nelson KB. The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med 1962;87:989-1008.
[PUBMED]
18. Frieze TW, Mong DP, Koops MK. "Hook effect" in prolactinomas: case report and review of literature. Endocr Pract 2002;8:296-303.
[CROSSREF] [PDF]
19. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273-288.
[CROSSREF] [PUBMED] [PDF]
20. Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim MS. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009;24:874-878.
[CROSSREF] [PUBMED] [PMC]
21. Iglesias P, Diez JJ. Macroprolactinoma: a diagnostic and therapeutic update. QJM 2013;106:495-504.
[CROSSREF] [PUBMED] [PDF]
22. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.
[CROSSREF] [PUBMED]
23. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2247-2252.
[CROSSREF] [PUBMED]
24. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.
[CROSSREF] [PUBMED]
25. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
[CROSSREF] [PUBMED]
26. Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. Arch Neurol 2007;64:1721-1726.
[CROSSREF] [PUBMED]
27. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
[CROSSREF] [PUBMED]
28. Valassi E, Klibanski A, Biller BM. Clinical review: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010;95:1025-1033.
[CROSSREF] [PUBMED] [PDF]
29. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3777-3784.
[CROSSREF] [PUBMED] [PDF]
30. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008;159:R11-R14.
[CROSSREF] [PUBMED]
31. Saeki N, Nakamura M, Sunami K, Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 1998;45:529-537.
[CROSSREF] [PUBMED]
32. Menucci M, Quinones-Hinojosa A, Burger P, Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 2011;14:68-74.
[CROSSREF] [PUBMED] [PMC]
33. Regal M, Paramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001;55:735-740.
[CROSSREF] [PUBMED]
34. Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Schutte PJ, Smit JW, Romijn JA, Pereira AM. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 2007;156:217-224.
[CROSSREF]
35. Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007;67:938-943.
[CROSSREF] [PUBMED]
36. Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, Diez JJ. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf) 2012;77:281-287.
[CROSSREF] [PUBMED]